Richmond Pharmacology is excited to join the AGAH Conference 2026 in Frankfurt, Germany, on 25- 26 February 2026.

Bringing together experts in clinical pharmacology and early-phase drug development, this conference is a key platform for advancing methodologies, regulatory strategies, and innovation in human pharmacology.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer and President at AGAH
  • Dr Lisa Campbell, Director of Regulatory Strategy
  • James Rickard, Chief Scientific Officer (Richmond Research Institute)
  • Elizabeth Romano, Director of Communications and Participant Engagement

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Innovations in early-phase trial design and execution
  • Regulatory frameworks for first-in-human studies
  • Biomarker-driven approaches to accelerate development
  • Patient-centric strategies in early-phase research
  • Collaboration between academia, industry, and regulators

Connect With Us

If you are attending AGAH Conference 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event